BRAF inhibitor–associated ERK activation drives development of chronic lymphocytic leukemia

Patients with BRAFV(600E/K)-driven melanoma respond to the BRAF inhibitor vemurafenib due to subsequent deactivation of the proliferative RAS/RAF/MEK/ERK pathway. In BRAF WT cells and those with mutations that activate or result in high levels of the BRAF activator RAS, BRAF inhibition can lead to E...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Invest
Main Authors: Yaktapour, Niuscha, Meiss, Frank, Mastroianni, Justin, Zenz, Thorsten, Andrlova, Hana, Mathew, Nimitha R., Claus, Rainer, Hutter, Barbara, Fröhling, Stefan, Brors, Benedikt, Pfeifer, Dietmar, Pantic, Milena, Bartsch, Ingrid, Spehl, Timo S., Meyer, Philipp T., Duyster, Justus, Zirlik, Katja, Brummer, Tilman, Zeiser, Robert
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2014
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4347247/
https://ncbi.nlm.nih.gov/pubmed/25329694
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI76539
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados